Christina Charles-Schoeman has received research grants from AbbVie, Alexion, Bristol-Myers Squibb, CSL Behring, Pfizer, and Priovant Therapeutics; and consulting fees from AbbVie, Bristol-Myers Squibb, Gilead, Pfizer, Recludix, and Sanofi/Regeneron. Jon T. Giles has received research grants from Pfizer; and consulting fees from AbbVie, Bristol-Myers Squibb, Eli Lilly, Gilead, Pfizer, and UCB. Nancy E. Lane has received consulting fees from Amgen, ANI, GSK, and Mallinckrodt. Ernest Choy has received research grants from Bio-Cancer, Biogen, Novartis, Pfizer, Roche, Sanofi, and UCB; consulting fees from AbbVie, Amgen, Biocon, Biogen, Chugai, Eli Lilly, Fresenius Kabi, Gilead, Janssen, Merck Serono, Novartis, Pfizer, Regeneron, Roche, R-Pharm, and Sanofi; and speaker fees from AbbVie, Amgen, Bristol-Myers Squibb, Chugai, Eli Lilly, Fresenius Kabi, Galapagos, Gilead, Janssen, Novartis, Pfizer, Regeneron, Roche, Sanofi, and UCB. Daniel E. Furst has received research grants from Actelion, Amgen, Bristol-Myers Squibb, Corbus, Galapagos, GSK, NIH, Novartis, Pfizer, Roche/Genentech, and Sanofi; consulting fees from AbbVie, Actelion, Amgen, Bristol-Myers Squibb, Corbus, Galapagos, Novartis, and Pfizer; and speaker fees from AbbVie, Continuing Medical Education, and Novartis. Jiří Vencovský has received consulting fees from AbbVie, Boehringer Ingelheim, Eli Lilly, Gilead, and Octapharma; and speaker bureau fees from AbbVie, Biogen, MSD, Pfizer, Roche, Sanofi, and UCB. Anthony G. Wilson has nothing to disclose. Gerd R. Burmester has received consulting fees and speaker bureau fees from AbbVie, Eli Lilly, Gilead, Janssen, MSD, Pfizer, Roche, and UCB. Derek Coombs, Sara K. Penn, Nasser Khan, Jillian B. Yee, and Kassim Rahawi are employees of AbbVie and may own stock or options. Iain B. McInnes has received research grants from Celgene, Eli Lilly, Janssen, Novartis, Pfizer, Roche, and UCB; and consulting fees from AbbVie, Amgen, Bristol-Myers Squibb, Cabaletta, Celgene, Compugen, Eli Lilly, Eyelo, Gilead, Janssen, Novartis, and UCB.

All clinical studies were conducted according to the International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use guidelines, applicable regulations and guidelines governing clinical study conduct, and the Declaration of Helsinki. As this was an integrated analysis of pooled clinical trial data, IRB approval was not required.